Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intercellular transfer of P-glycoprotein mediates the formation of stable multi-drug resistance in human bladder cancer BIU-87 cells.
|
30967374 |
2019 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Non-coding RNA NEAT1/miR-214-3p contribute to doxorubicin resistance of urothelial bladder cancer preliminary through the Wnt/β-catenin pathway.
|
30349370 |
2018 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that SNPs of NR1I2 and its target genes CYP3A5 and ABCB1 are genetic determinants of temsirolimus pharmacokinetics and toxicity in patients with bladder cancer.
|
28676933 |
2017 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nuclear expression of YB-1 was correlated with the expression of p-glycoprotein and p53 in bladder cancer cases (p<0.05).
|
28714514 |
2017 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that inhibiting ATR-Chk1 activation with WYC0209 suppresses p-glycoprotein expression and increases cisplatin activity in bladder cancer.
|
26657501 |
2016 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, IHC staining of human BCa tissue supported our conclusion that the expression of HIF-1α and MDR1 was higher in chemoresistant tissue vs. chemosensitive tissue.
|
26717965 |
2016 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
P-Glycoprotein-mediated multidrug resistance is a frequent event during chemotherapy and a key obstacle for bladder cancer therapy.
|
24601223 |
2014 |
Carcinoma of bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study was aimed at examining the local distribution of GSTM1, GSTT1, MDR1, and VEGF gene polymorphisms as possible risk factors contributing to the development of bladder cancer among the population from Canary Islands, Spain.
|
21292509 |
2012 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the molecular mechanism of doxorubicin resistance in bladder cancer with regard to p300.
|
21935574 |
2012 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We report a novel mechanism of anthracycline chemoresistance in bladder cancer in which activated Twist mediates P-gp expression in addition to its antiapoptotic roles.
|
22986993 |
2012 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Association of steroid and xenobiotic receptor (SXR) and multidrug resistance 1 (MDR1) gene expression with survival among patients with invasive bladder carcinoma.
|
20840328 |
2011 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prospective studies are warranted to define a role for MDR1 and ERCC1 analysis in individualizing multimodality treatment in locally advanced bladder cancer.
|
20689757 |
2010 |
Carcinoma of bladder
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
A statistically significant inverse correlation existed between MDR1 expression and the methylation of 5'CpG sites at the promoter in patients with bladder cancer after chemotherapeutic treatment, with the degree of methylation at several CpG sites, rather than other specific sites, involved in this regulation.
|
11156211 |
2000 |
Carcinoma of bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines.
|
7734314 |
1995 |
Carcinoma of bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Given that mdr1 mRNA levels are increased in a proportion of high-grade bladder tumours that are routinely subjected to chemotherapy, we discuss the possibility that mdr1 mRNA levels may be clinically significant as determinants of chemotherapeutic response and outcome in bladder cancer.
|
7908215 |
1994 |